Semaglutide denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Issue a Not-FDA-Approved Denial for Semaglutide

A not-FDA-approved denial in this context almost always means one of two things: (1) semaglutide is FDA-approved, but it is being prescribed for a specific use, formulation, route, or patient population that falls outside the approved labeling — commonly called off-label use — and Cigna's policy does not cover that particular off-label use; or (2) there is an administrative error in how the claim was coded. Understanding which situation applies is the first step in your appeal.

Semaglutide has received FDA approval for multiple distinct indications. If your prescribed use is covered by one of those approvals, the denial is factually incorrect and should be reversed on that basis alone. If the use is genuinely off-label, the appeal strategy shifts to demonstrating that the off-label use is supported by established medical evidence and professional society guidelines.

## Why This Denial Is Appealable

For an FDA-approved use: The denial is a factual error. Your appeal should attach the FDA-approved prescribing information, highlight the specific approved indication that applies to your diagnosis, and request immediate reversal.

For a genuinely off-label use: Many plans are required to cover off-label uses that are supported by established peer-reviewed evidence and recognized professional society guidelines, particularly for serious conditions. Cigna's own medical policy typically contains criteria for covering off-label drug use — your appeal should address those criteria directly.

## Your Federal Appeal Rights

• Internal appeal: File a written appeal under ERISA §503 (employer plans) or applicable state law (individual/fully-insured plans) within the timeframe shown on your denial notice.
• External review: Under ACA §2719, an independent review organization (IRO) can review whether the not-FDA-approved finding is accurate and whether any off-label use meets the plan's evidence standards. The external-review window is generally approximately four months from the final internal denial.
• Expedited review: Available when delay would seriously jeopardize your health.

## Documentation to Gather

1. FDA prescribing label: The complete, current FDA-approved prescribing information for semaglutide, with the specific approved indication that applies to your diagnosis clearly identified. 2. Diagnosis documentation: Chart records confirming your diagnosis, including the diagnosis code (ICD-10) used on the claim and supporting clinical evidence. 3. Claim coding review: Ask your prescriber or pharmacy to confirm the NDC code, indication code, and diagnosis codes submitted — a mismatch here can trigger a not-FDA-approved denial that has nothing to do with clinical appropriateness. 4. Professional society guidelines (off-label scenarios): If the use is off-label, a reference to the applicable clinical guideline organization that recognizes this use, without citing specific numeric thresholds. 5. Prescriber letter: A detailed letter explaining the clinical basis for the prescription, citing the FDA approval or, for off-label use, the supporting evidence base.

## Criteria-Mapping Structure

Obtain Cigna's medical policy for semaglutide and for off-label drug coverage. Address each applicable criterion:

| Criterion | Your Evidence | |-----------|---------------| | Is the use FDA-approved for this indication? | [Cite the specific FDA-approved indication from the label] | | If off-label: is it supported by recognized evidence? | [Professional society guideline reference, prescriber attestation] | | Is the submitted diagnosis consistent with the covered use? | [Diagnosis code, chart confirmation] | | Coding accuracy | [NDC code, prescriber confirmation of submitted codes] |

Correcting a not-FDA-approved denial often requires only a well-documented letter and the FDA label — do not let this denial go unchallenged.